RATIONALE: Cyclic AMP (cAMP)-protein kinase A signaling has been implicated in the regulation of ethanol consumption. Phosphodiesterase-4 (PDE4) specifically hydrolyzes cAMP and plays a critical role in controlling intracellular cAMP levels in the brain. However, the role of PDE4 in ethanol consumption remains unknown. OBJECTIVE: The objective of this study is to examine whether PDE4 was involved in regulating ethanol intake. METHODS: The two-bottle choice paradigm was used to assess intake of ethanol, sucrose, and quinine in C57BL/6J mice treated with the selective PDE4 inhibitor rolipram or Ro 20-1724; locomotor activity was also monitored using the open-field test in mice treated with rolipram. RESULTS: Administration (i.p.) of either rolipram (0.25 and 0.5 mg/kg) or Ro 20-1724 (10 mg/kg) reduced ethanol intake and preference by 60-80%, but did not alter total fluid intake. In contrast, rolipram even at the higher dose of 0.5 mg/kg was not able to affect intake of sucrose or quinine, alcohol-induced sedation, or blood ethanol elimination. At 0.5 mg/kg, rolipram did decrease locomotor activity, but the effect only lasted for approximately 40 min, which did not likely affect behavior of ethanol drinking. CONCLUSIONS: These results suggest that PDE4 is a novel target for drugs that reduce ethanol intake; PDE4 inhibitors may be used for treatment of alcohol dependence.
RATIONALE: Cyclic AMP (cAMP)-protein kinase A signaling has been implicated in the regulation of ethanol consumption. Phosphodiesterase-4 (PDE4) specifically hydrolyzes cAMP and plays a critical role in controlling intracellular cAMP levels in the brain. However, the role of PDE4 in ethanol consumption remains unknown. OBJECTIVE: The objective of this study is to examine whether PDE4 was involved in regulating ethanol intake. METHODS: The two-bottle choice paradigm was used to assess intake of ethanol, sucrose, and quinine in C57BL/6J mice treated with the selective PDE4 inhibitor rolipram or Ro 20-1724; locomotor activity was also monitored using the open-field test in mice treated with rolipram. RESULTS: Administration (i.p.) of either rolipram (0.25 and 0.5 mg/kg) or Ro 20-1724 (10 mg/kg) reduced ethanol intake and preference by 60-80%, but did not alter total fluid intake. In contrast, rolipram even at the higher dose of 0.5 mg/kg was not able to affect intake of sucrose or quinine, alcohol-induced sedation, or blood ethanol elimination. At 0.5 mg/kg, rolipram did decrease locomotor activity, but the effect only lasted for approximately 40 min, which did not likely affect behavior of ethanol drinking. CONCLUSIONS: These results suggest that PDE4 is a novel target for drugs that reduce ethanol intake; PDE4 inhibitors may be used for treatment of alcohol dependence.
Authors: Judith A Siuciak; Sheryl A McCarthy; Douglas S Chapin; Ashley N Martin Journal: Psychopharmacology (Berl) Date: 2007-12-01 Impact factor: 4.530
Authors: Han-Ting Zhang; Ying Huang; Anbrin Masood; Lisa R Stolinski; Yunfeng Li; Lei Zhang; Daniel Dlaboga; S-L Catherine Jin; Marco Conti; James M O'Donnell Journal: Neuropsychopharmacology Date: 2007-08-15 Impact factor: 7.853
Authors: Judith A Siuciak; Douglas S Chapin; Sheryl A McCarthy; Ashley N Martin Journal: Psychopharmacology (Berl) Date: 2007-03-02 Impact factor: 4.415
Authors: Anna Warden; Emma Erickson; Gizelle Robinson; R Adron Harris; R Dayne Mayfield Journal: Pharmacogenomics Date: 2016-12-05 Impact factor: 2.533
Authors: Yuri A Blednov; Cecilia M Borghese; Michael P Dugan; Swetak Pradhan; Thanvi M Thodati; Nikhita R Kichili; R Adron Harris; Robert O Messing Journal: Neuropharmacology Date: 2020-07-29 Impact factor: 5.250
Authors: Richard L Bell; Marcelo F Lopez; Changhai Cui; Mark Egli; Kirk W Johnson; Kelle M Franklin; Howard C Becker Journal: Addict Biol Date: 2013-11-11 Impact factor: 4.280
Authors: Marian L Logrip; Leandro F Vendruscolo; Joel E Schlosburg; George F Koob; Eric P Zorrilla Journal: Neuropsychopharmacology Date: 2014-01-29 Impact factor: 7.853